These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35914959)

  • 1. COVID-19 management landscape: A need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries.
    Pidiyar V; Kumraj G; Ahmed K; Ahmed S; Shah S; Majumder P; Verma B; Pathak S; Mukherjee S
    Vaccine; 2022 Aug; 40(36):5302-5312. PubMed ID: 35914959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries.
    Hussain A; Rafeeq H; Asif HM; Shabbir S; Bilal M; Mulla SI; Franco M; Iqbal HMN
    Int Immunopharmacol; 2021 Oct; 99():108050. PubMed ID: 34426120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.
    Hayman B; Dennehy M
    Vaccine; 2021 Aug; 39(36):5153-5161. PubMed ID: 34362602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
    Ameratunga R; Jordan A; Lehnert K; Leung E; Mears ER; Snell R; Steele R; Woon ST
    Antiviral Res; 2024 Jul; 227():105894. PubMed ID: 38677595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2.
    Baral PK; Yin J; James MNG
    Int J Biol Macromol; 2021 Sep; 186():490-500. PubMed ID: 34237371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccine and the cold chain implications for global adoption.
    Das MK
    Indian J Public Health; 2021; 65(3):307-310. PubMed ID: 34558497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed Access to COVID-19 Vaccines: A Perspective on Low-income Countries in Africa.
    Hassan MA; Aliyu S
    Int J Health Serv; 2022 Jul; 52(3):323-329. PubMed ID: 35469499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries.
    Aripov T; Wikler D; Asadov D; Tulekov Z; Murzabekova T; Munir KM
    BMC Med Ethics; 2022 Mar; 23(1):21. PubMed ID: 35264173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
    Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
    Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions.
    Abulsoud AI; El-Husseiny HM; El-Husseiny AA; El-Mahdy HA; Ismail A; Elkhawaga SY; Khidr EG; Fathi D; Mady EA; Najda A; Algahtani M; Theyab A; Alsharif KF; Albrakati A; Bayram R; Abdel-Daim MM; Doghish AS
    Biomed Pharmacother; 2023 Jan; 157():113977. PubMed ID: 36370519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Coming of Age of Nucleic Acid Vaccines during COVID-19.
    Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.